Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
RNA Editing02:23

RNA Editing

8.3K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
8.3K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early-onset hereditary spastic paraplegia type 56 (SPG56): clinical-molecular correlations and functional validation of CYP2U1 variants.

BMC medical genomics·2026
Same author

EnzymeMiner 2.0: advancing automated enzyme discovery with expansive sequence mining and smart property analysis.

Nucleic acids research·2026
Same author

Gene regulatory programs of cognitive resilience and pathogenesis in Alzheimer's disease.

medRxiv : the preprint server for health sciences·2026
Same author

Experimentally validated deep learning control of protein aggregation.

Communications chemistry·2026
Same author

ADAR1 and ADAR2 associate with the RNA exosome and modulate RNA stability.

Nucleic acids research·2026
Same author

Aicardi-Goutières Syndrome Type 6: Case Report and Structural Prediction Supporting a Dominant-Negative Effect of the <i>ADAR1</i> c.<i>3019G</i>>A Variant.

Clinical case reports·2026
Same journal

Corrigendum to "Antidiabetic sitagliptin influences tissue regeneration by affecting progenitor cells" [Biomed. Pharmacother. 189 (2025) 118279].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Corrigendum: "Zebrafish as a model to study inflammation: A tool for drug discovery" [Biomed. Pharmacother. 144 (2021) 112310].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Raloxifene and tamoxifen reshape the immunometabolic phenotype of TLRs-activated macrophages through AEBS inhibition and lysosomal stress.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Smart biomaterials in the dimensional revolution of bioprinting: From 2D to 6D for advanced biomedical applications.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

A trispecific GLP-1/anti-GIPR/FGF21 peptibody exhibits favorable metabolic effects in a diet-induced obesity model.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Malvidin and its glycosides in cancer treatment: Mechanisms, synergies and drug delivery strategies.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
See all related articles

Related Experiment Video

Updated: May 3, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.1K

Taurine inhibits apolipoprotein E4 aggregation.

Anthony Legrand1, Katerina Amruz Cerna2, Sérgio M Marques1

  • 1Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Kamenice 5, Brno 625 00, Czech Republic; International Clinical Research Center, St. Anne's University Hospital Brno, Pekarska 53, Brno 656 91, Czech Republic.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|May 1, 2026
PubMed
Summary
This summary is machine-generated.

Taurine prevents Apolipoprotein E4 (ApoE4) aggregation and shifts its molecular profile towards the benign ApoE3 isoform. This suggests taurine may offer a therapeutic strategy for ApoE4-related neurodegenerative diseases.

Keywords:
aggregationapolipoprotein E4taurinetherapeutic potential

More Related Videos

An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons
05:51

An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons

Published on: May 23, 2019

5.6K
In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening
09:49

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

21.3K

Related Experiment Videos

Last Updated: May 3, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.1K
An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons
05:51

An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons

Published on: May 23, 2019

5.6K
In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening
09:49

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

21.3K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Genetics

Background:

  • Apolipoprotein E4 (ApoE4) is a significant genetic risk factor for neurodegenerative diseases.
  • ApoE4 aggregation is a key pathological feature, and current therapeutic strategies are limited.
  • Tramiprosate and its metabolite modulate ApoE4 aggregation.

Purpose of the Study:

  • To investigate the mechanistic interactions between taurine and Apolipoprotein E4 (ApoE4).
  • To determine if taurine can modulate ApoE4 aggregation behavior, similar to tramiprosate.
  • To explore taurine's potential as a therapeutic agent for ApoE4-associated pathologies.

Main Methods:

  • Molecular dynamics simulations
  • Static light scattering
  • Mass spectrometry
  • Cerebral organoid models

Main Results:

  • Taurine effectively inhibits ApoE4 aggregation.
  • Taurine demonstrates a partial disaggregating effect on pre-formed ApoE4 aggregates.
  • Taurine modulates ApoE4 molecular and cellular features towards those of the ApoE3 isoform.

Conclusions:

  • Taurine influences ApoE4 aggregation and associated molecular mechanisms.
  • Taurine's effects are comparable to those of tramiprosate and 3-sulfopropanoic acid.
  • Taurine shows potential as a therapeutic intervention for the high-risk ApoE4/E4 genotype in neurodegenerative diseases.